Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Advaxis (ADXS) Share Price

News stories about Advaxis (NASDAQ:ADXS) have been trending somewhat positive this week, Accern reports. The research firm rates the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Advaxis earned a news sentiment score of 0.08 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 47.5129085727683 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Here are some of the media stories that may have impacted Accern Sentiment Analysis’s rankings:

How to Become a New Pot Stock Millionaire

Several equities research analysts have issued reports on ADXS shares. Cantor Fitzgerald cut their price objective on shares of Advaxis from $19.00 to $5.00 and set an “overweight” rating for the company in a research report on Tuesday, March 13th. ValuEngine upgraded shares of Advaxis from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. Finally, HC Wainwright set a $6.00 price target on shares of Advaxis and gave the company a “buy” rating in a research report on Wednesday, March 14th.

Advaxis stock traded up $0.03 during midday trading on Friday, hitting $1.90. 746,566 shares of the stock were exchanged, compared to its average volume of 1,332,252. Advaxis has a 52 week low of $1.75 and a 52 week high of $9.55. The firm has a market capitalization of $99.40, a P/E ratio of -0.80 and a beta of 1.06.

Advaxis (NASDAQ:ADXS) last released its quarterly earnings results on Monday, March 12th. The biotechnology company reported ($0.49) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.06. Advaxis had a negative net margin of 940.64% and a negative return on equity of 149.14%. The company had revenue of $2.06 million during the quarter, compared to the consensus estimate of $3.03 million. research analysts predict that Advaxis will post -1.73 EPS for the current year.

TRADEMARK VIOLATION WARNING: This piece of content was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3299433/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-advaxis-adxs-share-price.html.

About Advaxis

Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.

Insider Buying and Selling by Quarter for Advaxis (NASDAQ:ADXS)

Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Liberum Capital Reiterates Hold Rating for Sports Direct
Liberum Capital Reiterates Hold Rating for Sports Direct
RWS  Rating Reiterated by Shore Capital
RWS Rating Reiterated by Shore Capital
WPP’s  Hold Rating Reiterated at Deutsche Bank
WPP’s Hold Rating Reiterated at Deutsche Bank
Berenberg Bank Raises Ten Entertainment Group  Price Target to GBX 310
Berenberg Bank Raises Ten Entertainment Group Price Target to GBX 310
Evonik Industries  Given a €27.00 Price Target by UBS Analysts
Evonik Industries Given a €27.00 Price Target by UBS Analysts
eMagin  Sees Large Decline in Short Interest
eMagin Sees Large Decline in Short Interest


© 2006-2018 Ticker Report. Google+.